Analyst Price Targets — NVO
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 5, 2026 12:38 pm | — | BMO Capital | $45.00 | $47.19 | TheFly | Novo Nordisk price target lowered to $45 from $57 at BMO Capital |
| January 26, 2026 2:36 pm | Evan Seigerman | BMO Capital | $57.00 | $63.80 | StreetInsider | Novo Nordisk (NVO) PT Raised to $57 at BMO Capital |
| December 10, 2025 11:16 am | — | HSBC | $54.00 | $46.36 | TheFly | Novo Nordisk price target raised to $54 from $47 at HSBC |
| December 3, 2025 11:31 am | Thibault Boutherin | Morgan Stanley | $42.00 | $47.43 | TheFly | Novo Nordisk price target lowered to $42 from $43 at Morgan Stanley |
| November 25, 2025 9:26 am | Evan Seigerman | BMO Capital | $46.00 | $44.97 | StreetInsider | Novo Nordisk (NVO) PT Lowered to $46 at BMO Capital |
| October 14, 2025 11:29 am | Evan Seigerman | BMO Capital | $55.00 | $57.50 | TheFly | Novo Nordisk price target raised to $55 from $50 at BMO Capital |
| October 1, 2025 8:03 pm | — | HSBC | $70.00 | $59.17 | TheFly | Novo Nordisk upgraded to Buy from Hold at HSBC |
| September 29, 2025 8:29 am | — | Morgan Stanley | $47.00 | $55.61 | TheFly | Novo Nordisk downgraded to Underweight from Equal Weight at Morgan Stanley |
| July 31, 2025 8:46 am | — | HSBC | $57.00 | $48.89 | TheFly | Novo Nordisk downgraded to Hold from Buy at HSBC |
| July 23, 2025 8:08 pm | Jailendra Singh | Truist Financial | $48.00 | $70.03 | Benzinga | What's Going On With Hims & Hers Stock Wednesday? |
Latest News for NVO
Novo Nordisk will launch a more affordable authorised copy of its Ozempic diabetes drug in South Africa later this month, partnering with healthcare company Acino to expand patient access.
Novo Nordisk has made robust gains of 40% at the stock markets since April, supported by the success of oral Wegovy and attractive valuations. The Wegovy pill can see a nice revenue uptick in Q2 2026 going by recent data, and that can continue into the year as it gains approvals from international markets. Importantly, the pill has made gains even when competitor Eli Lilly's Foundayo has seen limited success, which…
The FDA's approval of Merck (NYSE:MRK | MRK Price Prediction) enlicitide decanoate, marketed as Lipfendra, marks the first once-daily oral PCSK9 inhibitor cleared for adults with high LDL cholesterol, including heterozygous familial hypercholesterolemia.
Danish drugmaker Novo Nordisk said on Friday that India's drug regulator has approved its obesity drug Wegovy for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease.
All three can be bought on the dip.
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for NVO.
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.